Recent advances of cocktail chemotherapy by combination drug delivery systems

Hu, Quanyin; Sun, Wujin; Wang, Chao; Gu, Zhen

doi:10.1016/j.addr.2015.10.022

Cited by 546 publications

(353 citation statements)

References 188 publications

Supporting

Mentioning

347

Contrasting

Unclassified

Order By: Relevance

“…Traditional combinations include methotrexate-based combinations (methotrexate plus cyclophosphamide/5-fluorouracyl (5-FU)), anthracycline-based combinations (Dox plus 5-FU) and taxane-based combinations (PTX plus cisplatin/carboplatin) [16]. Platinum compounds are also used in combination with other chemotherapeutic drugs in a clinical setting.…”

Section: Clinically Used Combination Chemotherapymentioning

confidence: 99%

“…Chemotherapy is also combined with a photothermal agent, a compound that generates cell-damaging hyperthermia in response to light stimulation [16], such as indocyanine dye [81], gold nanorods [82], and graphene [83]. For example, PTX was combined with indocyanine green (ICG) with human serum albumin (HSA) as a common carrier [84].…”

Section: Simultaneous Deliverymentioning

confidence: 99%

See 1 more Smart Citation

Organic nanoparticle systems for spatiotemporal control of multimodal chemotherapy

Meng¹,

Han²,

Yeo³

2016

Expert Opinion on Drug Delivery

View full text Add to dashboard Cite

Introduction Chemotherapeutic drugs are used in combination to target multiple mechanisms involved in cancer cell survival and proliferation. Carriers are developed to deliver drug combinations to common target tissues in optimal ratios and desirable sequences. Nanoparticles (NP) have been a popular choice for this purpose due to their ability to increase the circulation half-life and tumor accumulation of a drug. Areas covered We review organic NP carriers based on polymers, proteins, peptides, and lipids for simultaneous delivery of multiple anticancer drugs, drug/sensitizer combinations, drug/photodynamic- or photothermal therapy combinations, and drug/gene therapeutics with examples in the past three years. Sequential delivery of drug combinations, based on either sequential administration or built-in release control, is introduced with an emphasis on the mechanistic understanding of such control. Expert opinion Recent studies demonstrate how a drug carrier can contribute to co-localizing drug combinations in optimal ratios and dosing sequences to maximize the synergistic effects. We identify several areas for improvement in future research, including the choice of drug combinations, circulation stability of carriers, spatiotemporal control of drug release, and the evaluation and clinical translation of combination delivery.

show abstract

Section: Clinically Used Combination Chemotherapymentioning

confidence: 99%

Section: Simultaneous Deliverymentioning

confidence: 99%

Organic nanoparticle systems for spatiotemporal control of multimodal chemotherapy

Meng¹,

Han²,

Yeo³

2016

Expert Opinion on Drug Delivery

View full text Add to dashboard Cite

show abstract

“…This situation can be improved to some extent by cocktail or combination chemotherapy (i.e., the simultaneous administration of two or multiple therapeutic agents or drugs), of which the preliminary trials include doxorubicin (DOX), paclitaxel, and cisplatin based chemotherapeutics. [1][2][3] However, the traditional cocktail administration still suffers from uncontrollable pharmacokinetics among different drugs. On the other hand, the polymeric drug-loaded nanoparticles (i.e., the nanomedicine formulations) have presented distinct advantages including the enhancement of drug solubility, the prolongation of blood circulation time, the improvement of pharmacokinetics and pharmacodynamics, and especially the enhanced permeation and retention (EPR) effect in solid tumors compared to free drugs.…”

Section: Introductionmentioning

confidence: 99%

Plasmonic, Targeted, and Dual Drugs-Loaded Polypeptide Composite Nanoparticles for Synergistic Cocktail Chemotherapy with Photothermal Therapy

Zhou

et al. 2016

Biomacromolecules

View full text Add to dashboard Cite

To integrate cocktail chemotherapy with photothermal therapy into one biocompatible and biodegradable nanocarrier, the plasmonic, lactose-targeted, and dual anticancer drugs-loaded polypeptide composite nanoparticles were for the first time fabricated under mild conditions. The glyco-PEGylated polypeptide micelles that self-assembled from the lactose (LAC) and PEG grafted polycysteine terpolymer were used as templates to generate the plasmonic composite nanoparticles, as mainly characterized by DLS, TEM, SEM, and XPS. These composite nanoparticles showed a broad and strong near-infrared (NIR) absorption at 650-1100 nm and increased the temperature of phosphate buffer solution by 30.1 °C upon a continuous-wave laser irradiation (808 nm, 5 min, 2 W·cm(-2)), while the same dose of NIR-mediated heating completely killed HepG2 cancer cells in vitro, presenting excellent photothermal properties. Two anticancer drugs, doxorubicin (DOX) and 6-mercaptopurine (6-MP), were loaded into the composite nanoparticles through physical interactions and Au-S bond, respectively. The dual drugs-loaded composite nanoparticles exhibited reduction-sensitive and NIR-triggered cocktail drugs release profiles and trigger-enhanced cytotoxicity. As evidenced by flow cytometry, fluorescence microscopy, and MTT assay, the LAC-coated composite nanoparticles were more internalized by the HepG2 than the HeLa cell line, demonstrating a LAC-targeting enhanced cytotoxicity toward HepG2. The combination cocktail chemo-photothermal therapy produced a lower half maximal inhibitory concentration than cocktail chemotherapy or photothermal therapy alone, displaying a good synergistic antitumor effect.

show abstract

“…At last, the nucleus targeting anticancer drugs need to be further delivered to the nucleus for actions; the nuclear envelope is also the obstruction. In brief, we believe that continuous research efforts on NDCDS will provide some solutions to breaking the biological barrier to achieve the goal of effective cancer treatment (Hu et al, 2016).…”

Section: Safetymentioning

confidence: 99%

Co-delivery nanoparticles of anti-cancer drugs for improving chemotherapy efficacy

Sun

Yu³

et al. 2017

Drug Delivery

180

View full text Add to dashboard Cite

To achieve superior therapeutic efficacy, the combination chemotherapy using two or more anticancer drugs in clinical practice has been generally accepted as a feasible strategy. On account of the concept of combination chemotherapy, co-delivery of anticancer drugs with nanotechnology gradually becomes a desired strategy and one of the research frontiers on modern drug delivery. In recent years, nano drug co-delivery system (NDCDS), which loads at least two anticancer drugs with different physicochemical and pharmacological properties into a combination delivery system, has achieved rapid development. NDCDS synergistically inhibited the growth of the tumor compared with the free drugs. In this review, we highlighted the current state of co-delivery nanoparticles and the most commonly used nanomaterial, discussed challenges and strategies, and prospect future development. ARTICLE HISTORY

show abstract

Recent advances of cocktail chemotherapy by combination drug delivery systems

Cited by 546 publications

References 188 publications

Organic nanoparticle systems for spatiotemporal control of multimodal chemotherapy

Organic nanoparticle systems for spatiotemporal control of multimodal chemotherapy

Plasmonic, Targeted, and Dual Drugs-Loaded Polypeptide Composite Nanoparticles for Synergistic Cocktail Chemotherapy with Photothermal Therapy

Co-delivery nanoparticles of anti-cancer drugs for improving chemotherapy efficacy

Contact Info

Product

Resources

About